$HALB Halberd Corporation Plans to Extend Research
Post# of 25327
(Total Views: 135)
Posted On: 11/15/2023 9:03:27 AM
$HALB Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
https://www.accesswire.com/803506/halberd-cor...university
MSU Research for Halberd to Transcend the TBI Nasal Spray
JACKSON CENTER, PA / ACCESSWIRE / November 15, 2023 / Halberd Corporation (OTC PINK:HALB) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent TBI Nasal Spray project, as well as the proficiency, capabilities, efficiency, and professionalism exhibited by the MSU team. Notably, the positive interpersonal connections formed between Dr. Russell Carr, the Primary Investigator, and Halberd's scientific leaders have influenced this decision.
Dr. Carr remarked, "The preliminary investigation, spanning six months, confirmed the compelling effectiveness of Halberd's nasal spray in diminishing indicators of imminent brain damage following head trauma. Collaborating with Halberd's scientists has been a gratifying experience, and I am pleased to contribute to the team that validated the efficacy of their groundbreaking nasal spray product."
Mitchell S. Felder, M.D., the Chief Technology Officer at Halberd Corporation, a prolific inventor, and a board-certified attending neurologist, stated, "Our aim is to leverage the extended research collaboration duration at MSU to establish statistically significant findings regarding the efficacy of our patent-pending nasal spray in treating head trauma cases by mitigating the cascade of inflammatory cytokines and neurotransmitters, as well as explore the efficacy of additional products which Halberd has pending."
William A. Hartman, Chairman, President, and CEO of Halberd Corporation, commented, "We are highly satisfied with the efforts of Dr. Carr and the MSU staff and eagerly anticipate the ongoing and broadening scope of our research collaboration with them. Given the alarming rates of suicides and PTSD cases in our military, our primary focus is expediting the exposure of our technology to the US Department of Defense at the earliest opportunity."
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
https://www.accesswire.com/803506/halberd-cor...university
MSU Research for Halberd to Transcend the TBI Nasal Spray
JACKSON CENTER, PA / ACCESSWIRE / November 15, 2023 / Halberd Corporation (OTC PINK:HALB) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent TBI Nasal Spray project, as well as the proficiency, capabilities, efficiency, and professionalism exhibited by the MSU team. Notably, the positive interpersonal connections formed between Dr. Russell Carr, the Primary Investigator, and Halberd's scientific leaders have influenced this decision.
Dr. Carr remarked, "The preliminary investigation, spanning six months, confirmed the compelling effectiveness of Halberd's nasal spray in diminishing indicators of imminent brain damage following head trauma. Collaborating with Halberd's scientists has been a gratifying experience, and I am pleased to contribute to the team that validated the efficacy of their groundbreaking nasal spray product."
Mitchell S. Felder, M.D., the Chief Technology Officer at Halberd Corporation, a prolific inventor, and a board-certified attending neurologist, stated, "Our aim is to leverage the extended research collaboration duration at MSU to establish statistically significant findings regarding the efficacy of our patent-pending nasal spray in treating head trauma cases by mitigating the cascade of inflammatory cytokines and neurotransmitters, as well as explore the efficacy of additional products which Halberd has pending."
William A. Hartman, Chairman, President, and CEO of Halberd Corporation, commented, "We are highly satisfied with the efforts of Dr. Carr and the MSU staff and eagerly anticipate the ongoing and broadening scope of our research collaboration with them. Given the alarming rates of suicides and PTSD cases in our military, our primary focus is expediting the exposure of our technology to the US Department of Defense at the earliest opportunity."
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
(0)
(0)Scroll down for more posts ▼